Agarwal Sunil
SEC-identified person · CIK 1616640 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Catabasis Pharmaceuticals INC CATB | Director | filed 2024 - 2026 |
| Arvinas, INC. AVRN | Director | filed 2023 - 2025 |
| Calithera Biosciences, Inc. CALA | Director | filed 2015 - 2022 |
| Sana Biotechnology, Inc. SANA | See Remarks | filed 2021 - 2022 |
| Myokardia, Inc. MYOK | Director | filed 2016 - 2020 |
| Juno Therapeutics, Inc. JUNO | President of R & D | filed 2017 - 2018 |
| Ultragenyx Pharmaceutical Inc. RARE | Chief Medical Officer | filed 2014 - 2016 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.